Saltar al contenido
Merck

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Oncotarget (2017-12-07)
Mateusz Opyrchal, Malgorzata Gil, Jeffrey L Salisbury, Mathew P Goetz, Vera Suman, Amy Degnim, James McCubrey, Tufia Haddad, Ianko Iankov, Chenye B Kurokawa, Nicole Shumacher, James N Ingle, Evanthia Galanis, Antonino B D'Assoro
RESUMEN

Although the majority of breast cancers initially respond to the cytotoxic effects of chemotherapeutic agents, most breast cancer patients experience tumor relapse and ultimately die because of drug resistance. Breast cancer cells undergoing epithelial to mesenchymal transition (EMT) acquire a CD44

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
MISSION® esiRNA, targeting human SMAD5